NZ587010A - Sustained-release once-a-day oral dosage oxycodone formulations - Google Patents

Sustained-release once-a-day oral dosage oxycodone formulations

Info

Publication number
NZ587010A
NZ587010A NZ587010A NZ58701002A NZ587010A NZ 587010 A NZ587010 A NZ 587010A NZ 587010 A NZ587010 A NZ 587010A NZ 58701002 A NZ58701002 A NZ 58701002A NZ 587010 A NZ587010 A NZ 587010A
Authority
NZ
New Zealand
Prior art keywords
dosage form
oxycodone
hours
sustained
release
Prior art date
Application number
NZ587010A
Other languages
English (en)
Inventor
Benjamin Oshlack
Derek Allan Prater
Curtis Wright
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23106212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ587010(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NZ587010A publication Critical patent/NZ587010A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ587010A 2001-05-02 2002-05-02 Sustained-release once-a-day oral dosage oxycodone formulations NZ587010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28821101P 2001-05-02 2001-05-02
NZ576494A NZ576494A (en) 2001-05-02 2002-05-02 Once-a-day oxycodone formulations

Publications (1)

Publication Number Publication Date
NZ587010A true NZ587010A (en) 2012-03-30

Family

ID=23106212

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ529231A NZ529231A (en) 2001-05-02 2002-05-02 Once-a-day oxycodone formulations
NZ576494A NZ576494A (en) 2001-05-02 2002-05-02 Once-a-day oxycodone formulations
NZ587010A NZ587010A (en) 2001-05-02 2002-05-02 Sustained-release once-a-day oral dosage oxycodone formulations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ529231A NZ529231A (en) 2001-05-02 2002-05-02 Once-a-day oxycodone formulations
NZ576494A NZ576494A (en) 2001-05-02 2002-05-02 Once-a-day oxycodone formulations

Country Status (30)

Country Link
US (1) US7846476B2 (fr)
EP (5) EP3146963A1 (fr)
JP (5) JP4656815B2 (fr)
KR (9) KR101043492B1 (fr)
CN (2) CN1514721A (fr)
AU (1) AU2002303614B2 (fr)
CA (3) CA2601289C (fr)
CZ (2) CZ304442B6 (fr)
DK (3) DK2011485T3 (fr)
EA (1) EA005627B1 (fr)
ES (3) ES2523145T3 (fr)
HK (3) HK1128407A1 (fr)
HR (2) HRP20030951B1 (fr)
HU (1) HUP0401601A3 (fr)
IL (5) IL158723A0 (fr)
IS (1) IS7011A (fr)
MA (1) MA27128A1 (fr)
ME (1) ME00330B (fr)
MX (1) MXPA03010079A (fr)
NO (3) NO337039B1 (fr)
NZ (3) NZ529231A (fr)
PL (2) PL368901A1 (fr)
PT (2) PT2011485E (fr)
RS (3) RS52577B (fr)
SI (3) SI2011485T1 (fr)
SK (2) SK288220B6 (fr)
TN (1) TNSN03108A1 (fr)
UA (3) UA81224C2 (fr)
WO (1) WO2002087512A2 (fr)
ZA (1) ZA200308599B (fr)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
CA2446550C (fr) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP2308475A1 (fr) 2002-04-05 2011-04-13 Euro-Celtique S.A. Matrices pour libération modifiée des agents actives
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
CA2483655A1 (fr) * 2002-04-29 2003-11-13 Alza Corporation Procedes et formes dosifiees pour l'administration controlee d'oxycodone
CA2487786A1 (fr) * 2002-05-31 2003-12-11 Alza Corporation Formes galeniques et compositions d'administration osmotique de diverses posologies de l'oxycodone
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
EP2218448B1 (fr) 2002-12-13 2015-09-23 Durect Corporation Forme d'administration orale de medicaments comprenant un vehicule liquide de haute viscosite
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE602004032149D1 (de) * 2003-09-26 2011-05-19 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
MXPA06003450A (es) 2003-09-26 2006-08-31 Johnson & Johnson Recubrimiento de farmaco que proporciona alta carga del farmaco y metodos para proporcionar el mismo.
AU2004285547A1 (en) * 2003-10-29 2005-05-12 Alza Corporation Once-a-day, oral, controlled-release, oxycodone dosage forms
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
KR20080046751A (ko) * 2004-09-01 2008-05-27 유로-셀띠끄 소시에떼 아노님 용량 비례적 정상 상태 Ｃａｖｅ및 ＡＵＣ를 갖고, 용량비례적 단일 용량 Ｃｍａｘ보다 작은 오피오이드성 제형
WO2006030402A2 (fr) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Dispositif d'administration osmotique a deux compartiments
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006046114A2 (fr) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Formes posologiques osmotiques a taux croissant de liberation du medicament, et leurs procedes de preparation
TWI432196B (zh) * 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (fr) 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
EP1695700A1 (fr) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
MX2007012220A (es) * 2005-04-06 2007-12-06 Mallinckrodt Inc Formulacion farmaceutica de liberacion por pulsos a base de matriz.
DE102005048293A1 (de) * 2005-10-08 2007-04-12 Sanofi-Aventis Deutschland Gmbh Retardformulierung für Pralnacasan
FR2898056B1 (fr) * 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
EP2155167A2 (fr) 2007-06-04 2010-02-24 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
EP2219622A1 (fr) 2007-12-06 2010-08-25 Durect Corporation Procédés utiles dans le traitement de la douleur, d'états rhumatismaux ou d'inflammations associées à un état chronique
CA3066426A1 (fr) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Compositions pharmaceutiques renfermant un antiemetique et un analgesique opioide
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
PL2405915T3 (pl) 2009-03-10 2019-05-31 Euro Celtique Sa Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
EP2445487A2 (fr) 2009-06-24 2012-05-02 Egalet Ltd. Formulations à libération contrôlée
CA2767576C (fr) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Compositions pharmaceutiques refermant un antiemetique et un analgesiqueopioide
CA2765971C (fr) 2009-07-22 2017-08-22 Gruenenthal Gmbh Forme galenique extrudee a chaud a liberation controlee
CA2766172C (fr) 2009-07-22 2017-09-12 Lutz Barnscheid Forme galenique inviolable stabilisee a l'oxydation
IT1395143B1 (it) * 2009-08-06 2012-09-05 Sofar Spa Composizioni granulari a rilascio controllato di mesalazina e processo per il loro ottenimento.
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CA2798702A1 (fr) 2010-05-11 2011-11-17 Cima Labs Inc. Formes dosifiees orales a liberation prolongee contenant du metoprolol resistantes aux alcools
BR112013005194A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo sal inorgânico
CA2812570A1 (fr) * 2010-09-24 2012-03-29 QRxPharma Ltd. Formulations d'opioides a liberation controlee
KR200453833Y1 (ko) * 2010-10-18 2011-05-27 잘만테크 주식회사 냉각팬
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
WO2013000578A1 (fr) 2011-06-30 2013-01-03 Develco Pharma Schweiz Ag Forme posologique orale à libération contrôlée comprenant de l'oxycodone
EP2736497B1 (fr) 2011-07-29 2017-08-23 Grünenthal GmbH Comprimé multiparticulaire inviolable fournissant une libération immédiate de médicament
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
WO2013167990A1 (fr) 2012-05-07 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la dépression
WO2013167993A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de troubles neurologiques dégénératifs
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168025A1 (fr) 2012-05-08 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement des maladies de coagulation du sang
WO2013168016A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome métabolique
WO2013168000A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur sévère
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168015A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes pour le traitement de l'asthme et de l'allergie
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168014A1 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la polyneuropathie amyloïde familiale
WO2013167997A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement du syndrome métabolique
WO2013168004A2 (fr) 2012-05-10 2013-11-14 Mahesh Kandula Compositions et méthodes de traitement de la douleur fibromyalgique
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
EP2852570B1 (fr) 2012-05-23 2020-04-22 Cellixbio Private Limited Composition pour le traitement d'une maladie inflammatoire de l'intestin
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CA2873104A1 (fr) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions et methodes pour le traitement de la mucosite
WO2013175376A2 (fr) 2012-05-23 2013-11-28 Mahesh Kandula Compositions et méthodes de traitement de la douleur locale
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
EA201590165A1 (ru) 2012-07-06 2015-08-31 Эгалет Лтд. Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
WO2014085599A1 (fr) 2012-11-30 2014-06-05 Acura Pharmaceuticals, Inc. Libération autorégulée de principe pharmaceutique actif
CN104042581B (zh) * 2013-03-15 2016-10-19 中国药科大学 盐酸羟考酮缓控释制剂及其制备方法
EP2983468A4 (fr) 2013-03-15 2016-09-07 Durect Corp Compositions ayant un agent de modification rhéologique pour réduire une variabilité de dissolution
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014191397A1 (fr) 2013-05-29 2014-12-04 Grünenthal GmbH Forme pharmaceutique inviolable contenant une ou plusieurs particules
CA2914461A1 (fr) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions et procedes de traitement du diabete et du pre-diabete
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
MX2016000810A (es) 2013-07-23 2016-08-05 Euro Celtique Sa Combinacion de oxicodona y naloxona para su uso en el tratamiento de dolor en pacientes que sufren de dolor y una enfermedad que resulta la disbiosis intestinal y/o aumento del riesgo de la translocacion bacteriana intestinal.
WO2015023675A2 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération immédiate
EP3960162A1 (fr) * 2013-08-26 2022-03-02 Amorsa Therapeutics, Inc. Dose orale à couche unique de kétamine neuro-atténuante
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
US10227301B2 (en) 2015-01-06 2019-03-12 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (fr) 2014-05-26 2015-12-03 Grünenthal GmbH Microparticules protégées contre une libération massive dans l'éthanol
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
SG11201702554QA (en) 2014-09-29 2017-04-27 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
WO2017040607A1 (fr) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Procédés et compositions pour la libération auto-régulée d'un ingrédient pharmaceutique actif
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) * 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2020225773A1 (fr) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Formes posologiques dissuasives d'abus contenant de l'eskétamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA635283A (en) 1962-01-23 Olin Mathieson Chemical Corporation Pellets for prolonged drug action
US2738303A (en) 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2921883A (en) 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
NL263733A (fr) 1960-04-19 1900-01-01
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (fr) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
NL6714885A (fr) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3773920A (en) 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3965256A (en) 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3922339A (en) 1974-06-20 1975-11-25 Kv Pharm Co Sustained release medicant
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4036228A (en) 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
FI63335B (fi) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
CA1146866A (fr) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3208791A1 (de) * 1982-03-11 1983-09-22 Röhm GmbH, 6100 Darmstadt Verfahren zum ueberziehen von arzneiformen mittes eines in wasser dispergierten ueberzugsmittels
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
ZA836627B (en) 1982-10-08 1984-05-30 Verex Lab Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
EP0147780A3 (fr) 1984-01-03 1987-03-11 Merck & Co. Inc. Dispositif pour la libération d'un médicament
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4894234A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
JPS61152765A (ja) 1984-12-27 1986-07-11 Nippon Ekishiyou Kk シクロデキストリン類で包接された化合物を含有した合成樹脂製品及びその製造方法
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
GB2170104A (en) 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
NL8500724A (nl) 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
EP0204951B1 (fr) * 1985-05-13 1993-01-20 Miles Inc. Utilisation de calcibloqueurs dans la préparation de compositions pour les symptômes de la désintoxication
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ATE107857T1 (de) 1986-06-10 1994-07-15 Euro Celtique Sa Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4760094A (en) 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5219575A (en) 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5068110A (en) 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
EP0327295A3 (fr) 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Forme de dosage de la tétracycline
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
JP2850376B2 (ja) 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
US4983730A (en) * 1988-09-02 1991-01-08 Hoechst Celanese Corporation Water soluble cellulose acetate composition having improved processability and tensile properties
DE68916497T2 (de) 1988-09-30 1994-11-17 Rhone Poulenc Rorer Ltd Pharmazeutisches Granulat.
US5178868A (en) 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
CA2002492A1 (fr) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Compose pharmaceutique contenant une resine echangeuse d'ions
US5196203A (en) 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
CA2007181C (fr) 1989-01-06 1998-11-24 Angelo Mario Morella Compose pharmaceutique a liberation continue
CA2007055A1 (fr) 1989-01-06 1990-07-06 Garth Boehm Forme posologique de theophylline
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5326572A (en) 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5126145A (en) 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
FR2648020B1 (fr) 1989-06-12 1992-03-13 Rhone Poulenc Sante Utilisation de compositions degradables par voie enzymatique pour l'enrobage d'additifs alimentaires destines aux ruminants
DK161743C (da) 1989-07-03 1992-02-17 Niro Atomizer As Fremgangsmaade og apparat til agglomerering af et pulverformigt materiale
EP0415693A1 (fr) 1989-08-28 1991-03-06 Arizona Technology Development Corporation Composition et procédé pour la potentialisation sélective de l'effet des opiates et réduction de la tolérance et dépendance des opiates
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
IL96311A (en) 1989-12-01 1995-05-26 Abbott Lab Medications with delayed release
US5258436A (en) 1989-12-19 1993-11-02 Fmc Corporation Film-forming composition; method of producing same and use for coating pharmaceuticals and foods and the like
US5248516A (en) 1989-12-19 1993-09-28 Fmc Corporation Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like
IE66933B1 (en) 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5206030A (en) 1990-02-26 1993-04-27 Fmc Corporation Film-forming composition and use for coating pharmaceuticals, foods and the like
DK0452145T3 (da) 1990-04-12 1996-12-02 Shionogi & Co Overtrukket præparat og fremstilling deraf
JP2542122B2 (ja) 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
DE59105613D1 (de) 1990-08-24 1995-07-06 Spirig Ag Verfahren zur Herstellung von Pellets.
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5132142A (en) 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
EP0580860B2 (fr) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Procede de production d'une dispersion solide
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
MY110317A (en) 1991-09-06 1998-04-30 Mcneilab Inc Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone, and their use.
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5223541A (en) 1991-09-13 1993-06-29 Mcneilab, Inc. Tramadol n-oxide material, enantiomers and compositions thereof, and their use
GB9121204D0 (en) 1991-10-04 1991-11-20 Euro Celtique Sa Medicament
AU661723B2 (en) 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5167964A (en) 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
KR100304017B1 (ko) 1992-06-22 2001-11-22 추후제출 글리신수용체길항물질및이의용도
SE9202250D0 (sv) 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
CA2147283C (fr) 1992-10-16 2007-01-16 Kouichi Nakamichi Methode de fabrication de matrices de cire
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (fr) 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
SE9301057L (sv) 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4329794C2 (de) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5529787A (en) 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
WO1997033566A2 (fr) * 1996-03-12 1997-09-18 Alza Corporation Composition et forme galenique contenant un antagoniste des opioides
AU3404997A (en) * 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US5976579A (en) 1997-07-03 1999-11-02 Mclean; Linsey Nutritional supplement for the prevention and treatment of excessive intestinal permeability
US5959452A (en) * 1997-10-03 1999-09-28 The Johns Hopkins University Lorentz force magnetometer having a resonator
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
WO2001008661A2 (fr) * 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Preparation d'opioide a liberation continue
JP2004512354A (ja) * 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
JP2004534056A (ja) 2001-06-08 2004-11-11 エンドー ファーマシューティカルズ， インコーポレイティド アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
BR0205721A (pt) 2001-07-06 2003-09-30 Endo Pharmaceuticals Inc Formulações de oximorfona de liberação controlada
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
CA2483655A1 (fr) 2002-04-29 2003-11-13 Alza Corporation Procedes et formes dosifiees pour l'administration controlee d'oxycodone
CA2487786A1 (fr) 2002-05-31 2003-12-11 Alza Corporation Formes galeniques et compositions d'administration osmotique de diverses posologies de l'oxycodone
AU2004285547A1 (en) * 2003-10-29 2005-05-12 Alza Corporation Once-a-day, oral, controlled-release, oxycodone dosage forms

Also Published As

Publication number Publication date
NO341144B1 (no) 2017-09-04
SI2281555T1 (sl) 2016-06-30
HRP20030951B1 (hr) 2015-01-30
CA2601289A1 (fr) 2002-11-07
EP2269585A2 (fr) 2011-01-05
HRP20030951A2 (en) 2005-08-31
JP2009108083A (ja) 2009-05-21
KR101043492B1 (ko) 2011-06-23
SK14622003A3 (sk) 2004-08-03
KR20130100025A (ko) 2013-09-06
KR101366399B1 (ko) 2014-02-24
NO20034862L (no) 2003-12-29
SK288514B6 (sk) 2017-11-03
DK2281555T3 (en) 2016-06-06
ES2523145T3 (es) 2014-11-21
JP2015180669A (ja) 2015-10-15
US7846476B2 (en) 2010-12-07
EP2281555A3 (fr) 2012-07-18
KR20090037508A (ko) 2009-04-15
DK1416921T3 (da) 2014-11-03
TNSN03108A1 (en) 2005-12-23
KR20070030335A (ko) 2007-03-15
CZ305211B6 (cs) 2015-06-10
ES2530719T3 (es) 2015-03-04
CA2474904A1 (fr) 2002-11-07
SI1416921T1 (sl) 2015-01-30
JP5805707B2 (ja) 2015-11-04
KR20060028821A (ko) 2006-04-03
NO337039B1 (no) 2016-01-11
ME00330B (fr) 2011-05-10
NZ529231A (en) 2009-06-26
JP2004528338A (ja) 2004-09-16
CZ304442B6 (cs) 2014-05-07
EP2011485A3 (fr) 2010-04-21
PL368901A1 (en) 2005-04-04
RS20110564A3 (en) 2013-02-28
SI2011485T1 (sl) 2015-03-31
CZ20033242A3 (cs) 2004-06-16
JP2017114899A (ja) 2017-06-29
UA92115C2 (uk) 2010-09-27
WO2002087512A2 (fr) 2002-11-07
MEP49308A (en) 2011-02-10
PT1416921E (pt) 2014-10-20
PL221881B1 (pl) 2016-06-30
CA2601289C (fr) 2011-04-19
EP1416921A2 (fr) 2004-05-12
RS20120514A3 (en) 2014-02-28
UA88056C2 (uk) 2009-09-10
NO20160765L (no) 2003-12-29
IS7011A (is) 2003-10-31
UA81224C2 (uk) 2007-12-25
NO20034862D0 (no) 2003-10-31
HK1128407A1 (en) 2009-10-30
KR20110047282A (ko) 2011-05-06
RS52577B (en) 2013-04-30
IL223673A (en) 2016-10-31
MXPA03010079A (es) 2004-05-05
JP4656815B2 (ja) 2011-03-23
CA2474904C (fr) 2008-09-09
PL388076A1 (pl) 2005-04-04
NZ576494A (en) 2010-11-26
CN101627974B (zh) 2014-07-09
JP2013189461A (ja) 2013-09-26
HK1149722A1 (zh) 2011-10-14
CA2601222C (fr) 2013-02-12
RS20110564A2 (en) 2012-08-31
RS20120514A2 (en) 2013-06-28
NO20130159L (no) 2003-12-29
KR20130018960A (ko) 2013-02-25
IL211637A0 (en) 2011-05-31
KR100656730B1 (ko) 2006-12-13
CN1514721A (zh) 2004-07-21
ES2571703T3 (es) 2016-05-26
KR20100003308A (ko) 2010-01-07
CA2601222A1 (fr) 2002-11-07
JP5795138B2 (ja) 2015-10-14
YU86003A (sh) 2006-05-25
EP2269585A3 (fr) 2011-11-09
EP2281555B1 (fr) 2016-03-23
SK288220B6 (sk) 2014-08-05
WO2002087512A3 (fr) 2004-02-19
ZA200308599B (en) 2005-01-26
RS56252B1 (sr) 2017-11-30
PT2011485E (pt) 2015-02-05
EP1416921A4 (fr) 2006-08-09
EP2281555A2 (fr) 2011-02-09
HRP20140945A2 (hr) 2015-01-30
EP2011485A2 (fr) 2009-01-07
NO337963B1 (no) 2016-07-18
CN101627974A (zh) 2010-01-20
IL158723A0 (en) 2004-05-12
KR101476573B1 (ko) 2014-12-24
MA27128A1 (fr) 2005-01-03
EA200301165A1 (ru) 2004-06-24
HUP0401601A3 (en) 2008-05-28
HK1065482A1 (en) 2005-02-25
IL247971A0 (en) 2016-11-30
EP3146963A1 (fr) 2017-03-29
AU2002303614B2 (en) 2005-02-10
DK2011485T3 (en) 2015-01-19
EP2011485B1 (fr) 2014-12-03
IL158723A (en) 2013-12-31
KR20030096342A (ko) 2003-12-24
IL223673A0 (en) 2013-02-03
HUP0401601A2 (hu) 2004-11-29
EP1416921B1 (fr) 2014-08-06
EA005627B1 (ru) 2005-04-28
KR20120028993A (ko) 2012-03-23
IL211637A (en) 2017-04-30
US20040170680A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
US10660886B2 (en) Oxycodone formulations
CA2601222C (fr) Formulations d'oxycodone a administration quotidienne unique
US9205055B2 (en) Controlled release hydrocodone formulations
AU2002303614A1 (en) Once-a-day oxycodone formulations
AU2002227383A1 (en) Controlled Release Hydrocodone Formulations

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed
S35A Application for proceedings under section 35 (restoration of lapsed patents)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2017 BY THOMSON REUTERS

Effective date: 20160415

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAY 2018 BY ANAQUA SERVICES

Effective date: 20170420

LAPS Patent lapsed